Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China
Background: Treatment options for patients with refractory inflammatory bowel disease (IBD) or concomitant IBD and extraintestinal manifestations (EIM) are often limited. Objective: This study aimed to examine the efficacy and safety of combining biologics or small molecules in patients with refract...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/17562848241307598 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561005961773056 |
|---|---|
| author | Xiuxiu Jin Kefang Sun Liying Wang Haiyan Shen Dan Ma Tejia Shen Chunxiao Chen Lan Li |
| author_facet | Xiuxiu Jin Kefang Sun Liying Wang Haiyan Shen Dan Ma Tejia Shen Chunxiao Chen Lan Li |
| author_sort | Xiuxiu Jin |
| collection | DOAJ |
| description | Background: Treatment options for patients with refractory inflammatory bowel disease (IBD) or concomitant IBD and extraintestinal manifestations (EIM) are often limited. Objective: This study aimed to examine the efficacy and safety of combining biologics or small molecules in patients with refractory IBD, active EIM, or active immune-mediated inflammatory disease (IMID). Design: This was a retrospective and multicenter study. Methods: We retrospectively collected demographics and disease characteristics from 47 patients with IBD who received dual-targeted therapy in 3 hospitals from January 2022 to June 2024. The primary endpoint was clinical remission based on the Harvey–Bradshaw index or patient-reported outcome 2 after at least 4 months of combination therapy. The secondary endpoints included clinical response, endoscopic response, and endoscopic remission, as well as all adverse events that occurred within the period of combination therapy. Results: In total, 47 IBD patients including 37 with refractory IBD, 5 with active EIM, and 5 with active IMID received dual-targeted therapy, of which 37 achieved clinical response (78.7%) and 27 achieved clinical remission (57.4%) at a median follow-up time of 13.0 months. Among these 47 patients, 29 patients underwent endoscopic follow-up, of which 15 (51.7%) achieved endoscopic response and 8 (27.6%) achieved endoscopic remission at a median follow-up time of 9.0 months. Mild and moderate adverse events were reported in 17 (36.2%) patients within the period of combination therapy, and serious adverse events requiring hospitalization occurred in 1 patient (2.1%). Conclusion: The combination therapy of biologics and small molecules for refractory IBD or those with concomitant EIM/IMID is effective and safe. |
| format | Article |
| id | doaj-art-f134b86c7b5648fe92cfd568e0b0fa13 |
| institution | Kabale University |
| issn | 1756-2848 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj-art-f134b86c7b5648fe92cfd568e0b0fa132025-01-03T09:04:28ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482025-01-011810.1177/17562848241307598Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in ChinaXiuxiu JinKefang SunLiying WangHaiyan ShenDan MaTejia ShenChunxiao ChenLan LiBackground: Treatment options for patients with refractory inflammatory bowel disease (IBD) or concomitant IBD and extraintestinal manifestations (EIM) are often limited. Objective: This study aimed to examine the efficacy and safety of combining biologics or small molecules in patients with refractory IBD, active EIM, or active immune-mediated inflammatory disease (IMID). Design: This was a retrospective and multicenter study. Methods: We retrospectively collected demographics and disease characteristics from 47 patients with IBD who received dual-targeted therapy in 3 hospitals from January 2022 to June 2024. The primary endpoint was clinical remission based on the Harvey–Bradshaw index or patient-reported outcome 2 after at least 4 months of combination therapy. The secondary endpoints included clinical response, endoscopic response, and endoscopic remission, as well as all adverse events that occurred within the period of combination therapy. Results: In total, 47 IBD patients including 37 with refractory IBD, 5 with active EIM, and 5 with active IMID received dual-targeted therapy, of which 37 achieved clinical response (78.7%) and 27 achieved clinical remission (57.4%) at a median follow-up time of 13.0 months. Among these 47 patients, 29 patients underwent endoscopic follow-up, of which 15 (51.7%) achieved endoscopic response and 8 (27.6%) achieved endoscopic remission at a median follow-up time of 9.0 months. Mild and moderate adverse events were reported in 17 (36.2%) patients within the period of combination therapy, and serious adverse events requiring hospitalization occurred in 1 patient (2.1%). Conclusion: The combination therapy of biologics and small molecules for refractory IBD or those with concomitant EIM/IMID is effective and safe.https://doi.org/10.1177/17562848241307598 |
| spellingShingle | Xiuxiu Jin Kefang Sun Liying Wang Haiyan Shen Dan Ma Tejia Shen Chunxiao Chen Lan Li Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China Therapeutic Advances in Gastroenterology |
| title | Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China |
| title_full | Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China |
| title_fullStr | Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China |
| title_full_unstemmed | Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China |
| title_short | Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China |
| title_sort | efficacy and safety of dual targeted therapy for inflammatory bowel disease a retrospective multicenter study in china |
| url | https://doi.org/10.1177/17562848241307598 |
| work_keys_str_mv | AT xiuxiujin efficacyandsafetyofdualtargetedtherapyforinflammatoryboweldiseasearetrospectivemulticenterstudyinchina AT kefangsun efficacyandsafetyofdualtargetedtherapyforinflammatoryboweldiseasearetrospectivemulticenterstudyinchina AT liyingwang efficacyandsafetyofdualtargetedtherapyforinflammatoryboweldiseasearetrospectivemulticenterstudyinchina AT haiyanshen efficacyandsafetyofdualtargetedtherapyforinflammatoryboweldiseasearetrospectivemulticenterstudyinchina AT danma efficacyandsafetyofdualtargetedtherapyforinflammatoryboweldiseasearetrospectivemulticenterstudyinchina AT tejiashen efficacyandsafetyofdualtargetedtherapyforinflammatoryboweldiseasearetrospectivemulticenterstudyinchina AT chunxiaochen efficacyandsafetyofdualtargetedtherapyforinflammatoryboweldiseasearetrospectivemulticenterstudyinchina AT lanli efficacyandsafetyofdualtargetedtherapyforinflammatoryboweldiseasearetrospectivemulticenterstudyinchina |